Solventum Corporation $SOLV Shares Newly Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new stake in Solventum Corporation (NYSE:SOLV) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 36,857 shares of the company’s stock, valued at approximately $3,249,000.

Several other institutional investors have also added to or reduced their stakes in SOLV. ProShare Advisors LLC raised its holdings in Solventum by 9.0% during the 3rd quarter. ProShare Advisors LLC now owns 33,224 shares of the company’s stock valued at $2,929,000 after acquiring an additional 2,733 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in shares of Solventum by 147.7% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 32,700 shares of the company’s stock worth $2,883,000 after buying an additional 19,500 shares in the last quarter. Choreo LLC boosted its position in shares of Solventum by 2.9% in the third quarter. Choreo LLC now owns 12,910 shares of the company’s stock valued at $1,138,000 after acquiring an additional 368 shares during the period. Motley Fool Asset Management LLC grew its stake in Solventum by 43.8% during the third quarter. Motley Fool Asset Management LLC now owns 5,109 shares of the company’s stock valued at $450,000 after acquiring an additional 1,555 shares in the last quarter. Finally, North Dakota State Investment Board increased its holdings in Solventum by 3.1% during the 3rd quarter. North Dakota State Investment Board now owns 4,525 shares of the company’s stock worth $399,000 after acquiring an additional 134 shares during the period.

Wall Street Analyst Weigh In

SOLV has been the topic of a number of research analyst reports. Piper Sandler reissued an “overweight” rating and issued a $110.00 price target (up from $105.00) on shares of Solventum in a report on Friday. Wedbush lifted their price target on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Mizuho set a $113.00 price objective on Solventum in a report on Thursday, August 6th. KeyCorp increased their price objective on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, Canadian Imperial Bank of Commerce set a $35.00 target price on Solventum in a research report on Wednesday, October 28th. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Solventum currently has a consensus rating of “Moderate Buy” and an average price target of $90.27.

More Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Solventum earned $1.45 per share on $1.95 billion in revenue, beating consensus estimates of $1.34–$1.35 per share and $1.93 billion in sales. The company raised its 2026 adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 results
• Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an overweight rating; Wells Fargo increased its target to $95 while retaining an equal-weight rating. Jefferies raised its target to $98. Piper Sandler rating
• Neutral Sentiment: The company said the 7% year-over-year sales decline (organic sales down 2.8%) reflected, in part, a temporary ERP transition effect: customers had placed advance orders in the prior quarter ahead of the system cutover. Solventum also reported that its separation process was more than 90% complete. Q3 earnings and ERP impact
• Negative Sentiment: Despite the quarterly beat, revenue fell 7% year over year and EPS was down from $1.50 a year ago, highlighting ongoing comparisons and execution risks. Quarterly earnings details

Solventum Trading Up 3.6%

SOLV stock traded up $3.17 during trading on Friday, hitting $90.34. 3,168,921 shares of the company traded hands, compared to its average volume of 1,109,088. The company has a 50-day moving average of $87.73 and a 200-day moving average of $78.70. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $94.16. The firm has a market capitalization of $15.38 billion, a PE ratio of 101.51, a P/E/G ratio of 1.24 and a beta of 0.69.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.11. The company had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.93 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%. Solventum’s quarterly revenue was down 7.0% on a year-over-year basis. During the same period last year, the firm earned $1.50 earnings per share. Analysts predict that Solventum Corporation will post 7.21 earnings per share for the current fiscal year.

Solventum Company Profile

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.